HURDEN, Switzerland,
Jan. 21, 2022 /PRNewswire/ --
IDEOGEN GROUP, Managed Access division, takes over
Special Access Program for BELEODAQ® (belinostat) in
Europe, Middle East, North
Africa, Russia, and
CIS.
BELEODAQ® is a prescription medicine used to treat
patients with a rare form of blood cancer called peripheral T-cell
lymphoma (PTCL) that relapsed or does not respond to previous
treatment. PTCL is a group of rare and aggressive non-Hodgkin
lymphomas (NHL), a malignant lymphoproliferative disorder. PTCL
accounts for approximately 10%-15% of all NHL cases.
BELEODAQ® (belinostat) is the only
Histone Deacetylase Inhibitor ('HDAC inhibitor') globally to treat
refractory/relapsed PTCL. The product received accelerated approval
by the US Food and Drug Administration ('FDA') due to this rare
disease's high unmet medical need.
Murat Göker, Chief Commercial Officer at Ideogen
Group, commented: "Our modus operandi is to serve the unmet medical
needs of patients at the Speed of Life. As the trusted partner, we
service access for patients globally affected by underserved
diseases. Our Special Access Programs allow physicians access to
medicines like BELEODAQ® (belinostat) for special
circumstances of individual patients when alternative treatment
options are required.
"We are privileged to be the exclusive fulfilment partner
representing BELEODAQ® for immediate availability
across many territories*. Due to the time-sensitive
disease state of the relapsed/refractory PTCL
patient, BELEODAQ® is warehoused in the
EU and available for delivery to any ordering pharmacist or
physician within continental Europe with rapid deployment,"
states Mehmet Göker, Chief Operations Officer.
Healthcare professionals can obtain details about the
BELEODAQ® Special Access Program by calling an Ideogen
representative at +800 22 44 77 00 or emailing
healthcare@Ideogen.com.
About IDEOGEN: We focus on commercializing specialty
medicines with challenging and evolving healthcare dynamics. With
the operational infrastructure and know-how to handle activities
from unlicensed through licensed medicines, Ideogen sustains a
strong network of professionals and caretakers, nurturing sound
medical alliances for the benefit of patients.
Our portfolio focuses on medications that require expertise in
solving challenging Regulatory, Market Access, Quality, PV, and
fulfilment requirements for specialized disease segments. From
initial inquiry through timely delivery, we are reachable 24/7
internationally.
For more information, also visit www.ideogen.com
*Exclusive Coverage of
Territories: Albania , Algeria, Armenia, Austria, Bahrain, Belgium, Bosnia, Bulgaria, Croatia, Cyprus, Czech-Republic , Denmark, Djibouti, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Iran, Iraq,
Ireland, Israel, Italy, Jordan, Kazakhstan, Kirgizstan, Kuwait, Latvia, Lebanon, Libya, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Morocco, Netherlands, Norway, Oman,
Palestine, Poland, Portugal, Qatar, Romania, Russia, Saudi
Arabia, Serbia, Slovakia,
Slovenia, Spain, Sweden, Switzerland, Syria, Turkey, Tunisia, Ukraine, UK, Uzbekistan, UAE, and Yemen
Logo:
https://mma.prnewswire.com/media/1730926/Ideogen_Logo.jpg
For Media Relations, please contact:
info@idoegen.com; bettina.wassmann@ideogen.com; phone: +41 43 311
5252